"Diet Drug Acomplia Might Lower Liver Damage", Reveals New Research
16 July, 2007
Mulling the findings of a new animal study, the controversial drug acomplia could help users in reducing the liver damage other than elimination of obesity alone.
Under the new animal study conducted on anti-obesity
drug, the preparation was found effective for the treatment of one
more health concern. A latest rage among obese, Acomplia
lessened liver damage pertaining to obesity during the research
conducted on obese rats. The obesity-related liver damage can even
lead to liver cirhossis.
In the study centered on the liver function in obese rats, researchers noticed that rimonabant abridged the markers of liver damage as well as the levels of pro-inflammatory proteins. In addition, they also found improved lipid profiles.
Male obese rats were medicated with acomplia regularly for 8 weeks and their food intake was also monitored. In the conclusion, rats treated with rimonabant were found with reduced liver enlargement along with absolutely abolished hepatic steatosis, and reduced blood levels of enzyme markers which signify liver damage.
Besides, the drug also remarkably alleviated the levels of hepatic TNFa, a pro-inflammatory protein that is believed to be responsible for the encouragement of insulin resistance in the liver and progression of steatosis to hepatic fibrosis and cirrhosis.
Our theory is centered on the assumption that the multi-protective effects of the diet drug acomplia can be exploited both for reduction of pro-inflammatory cytokines like TNFa and amplification of anti-inflammatory and protective cytokines or hormones like adiponectin," the researchers articulated.
This recommends a possible clinical application of this CB1 receptor antagonist for the cure of liver ailments related to obesity and the metabolic syndrome," they added.
